Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

NCT04183088 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: Tislelizumab+regorafenib for part 1;Tislelizumab+regorafenib for group 1 of part 2; Regorafenib for group 2 of part 2.

Sponsor

National Taiwan University Hospital

Collaborators

[object Object]